ibandronic acid has been researched along with goserelin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Budischewski, K; du Bois, A; Jackisch, C; Kaufmann, M; Loibl, S; Lux, MP; Maass, N; Nestle-Kraemling, C; Paepke, S; Schmutzler, R; Vescia, S; von Minckwitz, G; Wallwiener, D | 1 |
1 review(s) available for ibandronic acid and goserelin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ibandronic acid and goserelin
| Article | Year |
|---|---|
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Goserelin; Hot Flashes; Humans; Ibandronic Acid; Mass Screening; Middle Aged; Premenopause; Prognosis; Risk Factors | 2011 |